Product Description
Ciprofloxacin is used to treat bacterial infections in many different parts of the body. Ciprofloxacin oral liquid and tablets are also used to treat anthrax infection after inhalational exposure. This medicine is also used to treat and prevent plague (including pneumonic and septicemic plague). Ciprofloxacin may mask or delay the symptoms of syphilis. It is not effective against syphilis infections. (Sourced from: https://www.mayoclinic.org/drugs-supplements/ciprofloxacin-oral-route/description/drg-20072288)
Mechanisms of Action: CYP1A2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Inhalant,Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Anthrax | Gonorrhea | Plague | Typhoid Fever | Respiratory Tract Infections | Urinary Tract Infections | Prostatitis | Cystitis | Nephritis | Pyelonephritis | Bronchitis | Bronchitis, Chronic | Sinusitis | Diarrhea | Urinary Tract Infections | Nephritis | Pyelonephritis | Otitis | Otitis Externa | Otitis | Otitis Externa | Otitis Media | Haemophilus Infections | Pneumonia, Bacterial | Pseudomonas Infections | Pneumonia | Influenza, Human | Otitis | Otitis Media | Pneumonia, Bacterial | Pneumonia | Influenza, Human
Known Adverse Events: Colitis | Hepatitis | Hepatitis, Chronic | Myasthenia Gravis | Drug Hypersensitivity | Hypersensitivity, Immediate | Anthrax | Central Nervous System Bacterial Infections | Gonorrhea | Plague | Typhoid Fever | Respiratory Tract Infections | Urinary Tract Infections | Muscle Weakness | Hypokalemia | Prostatitis | Cystitis | Nephritis | Pyelonephritis | Bronchitis | Bronchitis, Chronic | Sinusitis | Asthenia | Diarrhea | Lower Urinary Tract Symptoms | Signs and Symptoms, Respiratory | Dizziness | Headache | Pain Unspecified | Superinfection | Pruritus | Panic Disorder | Ranula
Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Spain, United States
Active Clinical Trial Count: 5
Highest Development Phases
Phase 3: Acute Respiratory Distress Syndrome|Bronchitis|Fractures, Open|Pneumonia|Pneumonia, Ventilator-Associated
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| DURATIOM | P3 |
Unknown Status |
Fractures, Open |
2027-12-31 |
|
| PKH-95032-009 | P1 |
Recruiting |
Healthy Volunteers |
2023-08-09 |
|
| NST-PK-003 | P1 |
Completed |
Healthy Volunteers |
2022-08-19 |
28% |
| NST-PK-003 | P1 |
Completed |
Healthy Volunteers |
2022-08-19 |
28% |
| ASPIC | P3 |
Active, not recruiting |
Pneumonia|Acute Respiratory Distress Syndrome |
2021-07-27 |